Prescient Therapeutics Limited logo

Prescient Therapeutics Limited

Prescient Therapeutic (PTX) is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. Prescient Therapeutics (formerly Virax Holdings) (ASX:PTX) is a biopharma company, focused in discovery and development of immunotherapeutic products for the treatment of chronic infectious diseases and cancer.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”PTX.AX” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://ptxtherapeutics.com
Founded2011
Disease Focus
Development Stage
STOCK CODEASX: PTX
Address
Level 4100 Albert Road, VIC, 3205
South Melbourne
Australia
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/prescient-therapeutics” connections=”true” suffix=””]

Prescient has two discovery platforms- 1) Co-X-Gene_ technology enabling co-expression of antigens and cytokines in DNA vaccines so as to manipulate the immune system in the appropriate fashion to treat disease. 2) FPV delivery technology consists of Fowlpox Virus (FPV) as the delivery vehicle.